<p>MicroPort Scientific Corporation said its affiliate Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec), in which it holds a 40.32% stake, reported unaudited 2025 revenue of RMB 1.35 billion, up 11.96% year on year. Endovastec posted profit of RMB 653.37 million and net profit attributable to equity owners of RMB 563.21 million, while total assets rose to RMB 4.64 billion and equity attributable to owners increased to RMB 4.08 billion as of Dec. 31, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032600), on February 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

02252

159898

02172

02160

00853

562600

<p>MicroPort Scientific Corporation's affiliate, Endovastec, reported unaudited 2025 revenue of RMB 1.35 billion, marking an 11.96% increase year-on-year. The company achieved a profit of RMB 653.37 million, with a net profit attributable to equity owners of RMB 563.21 million. As of December 31, 2025, total assets reached RMB 4.64 billion, and equity attributable to owners rose to RMB 4.08 billion.</p>

MicroPort Affiliate Endovastec Posts 2025 Revenue Growth to RMB1.35 Billion